CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-508861-34-00

Acronym

DR220214

Enrollment

Registered

2025-02-25

Start date

2025-12-02

Completion date

Unknown

Last updated

2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumocystis pneumonia

None listed

Sex/Gender

All

Age

18 Years to No maximum

France

None listed

Source: EU CTIS · Data processed: Feb 4, 2026